Alogliptin

• Type 2 Diabetes Mellitus
• Blood Sugar Control
• Glycemic Management

Alogliptin (brand name Nesina) is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes. It is a weight-neutral, once-daily option with a low intrinsic risk of hypoglycemia, often added when metformin alone is no longer keeping the A1c at target and a patient prefers an oral agent over an injectable. Because alogliptin is renally eliminated and does not require titration, it can be a practical choice for older adults and patients who struggle with complex regimens. The medication received FDA approval in 2013 and is available both as a single agent and in fixed-dose combinations with metformin or with pioglitazone for patients who benefit from combined mechanisms in one tablet. Within the broader landscape of diabetes mellitus care, DPP-4 inhibitors fill the niche of a quiet, predictable, well-tolerated oral option for patients who do not have indications for newer agents with cardiovascular or renal benefits.

Mechanism of Action

Alogliptin selectively and reversibly inhibits the DPP-4 enzyme, which normally degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) within minutes of their release from the gut. By prolonging endogenous incretin activity, alogliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon release from alpha cells. The glucose-dependent nature of this effect is what gives DPP-4 inhibitors their favorable hypoglycemia profile — insulin is only stimulated when blood glucose is elevated, so the medication does not push glucose below the normal range. Unlike GLP-1 receptor agonists such as semaglutide or liraglutide, DPP-4 inhibitors raise incretin levels into the physiologic range rather than supraphysiologic levels. This is why they typically produce smaller A1c reductions (around 0.5-0.8 percentage points) and minimal weight change, but also why they avoid the GI side effects, slowed gastric emptying, and appetite suppression characteristic of the GLP-1 class. Alogliptin reaches peak plasma concentration about an hour after dosing and has a half-life of 21 hours, supporting once-daily administration. The drug is primarily eliminated unchanged in the urine, which is why renal function determines the appropriate dose.

Clinical Use

Alogliptin is most often used as second- or third-line therapy after metformin, particularly when SGLT2 inhibitors like empagliflozin or dapagliflozin, or GLP-1 agonists, are contraindicated, not tolerated, or unaffordable. It is a reasonable alternative to other DPP-4 inhibitors such as sitagliptin, linagliptin, and saxagliptin; the class effects are similar, though linagliptin requires no renal dose adjustment and saxagliptin has been associated with a slightly higher heart-failure signal. Current American Diabetes Association Standards of Care generally favor agents with proven cardiovascular or renal benefit (SGLT2 inhibitors, GLP-1 agonists) in patients with established atherosclerotic disease, heart failure, or chronic kidney disease — DPP-4 inhibitors are best reserved for patients without those compelling indications. The EXAMINE trial confirmed cardiovascular safety in patients with recent acute coronary syndrome but did not demonstrate cardiovascular benefit. Patients living with diabetes mellitus often need combination therapy, and alogliptin pairs well with metformin or pioglitazone. For an introduction to the class structure of diabetes medications and where they fit, see our overview of GLP-1 medications — even though DPP-4 inhibitors are not GLP-1 agonists, they share the incretin pathway. Lifestyle changes including the Mediterranean dietary pattern and the strategies in our Pinellas County diabetes prevention guide remain foundational regardless of which medications are selected.

How to Take It

Alogliptin is taken once daily, with or without food, ideally at the same time each day to build a routine. Many patients pair it with a daily activity like brushing teeth or having morning coffee. If a dose is missed and it is still the same day, take it as soon as you remember; if it is nearly time for the next dose, skip the missed dose — do not double up. Store tablets at room temperature away from moisture; the bathroom medicine cabinet is actually a poor choice because of humidity, and a kitchen drawer or bedside table is preferable. In the first one to two weeks, most patients notice no change in how they feel; the medication works quietly in the background. Fasting glucose typically improves within days, but the full effect on A1c takes about three months to mature because the A1c reflects average glucose over the lifespan of red blood cells. Do not stop alogliptin abruptly without speaking to your prescriber, even if home glucose readings look excellent — discontinuation usually leads to gradual loss of glycemic control over weeks. Carry a current medication list and let any new healthcare provider know you take a DPP-4 inhibitor before being prescribed insulin or sulfonylureas, because dose reduction of those agents is often warranted to prevent hypoglycemia.

Monitoring and Follow-Up

A hemoglobin A1c is recommended every three months until at goal, then every six months for stable patients. Baseline and periodic kidney function (serum creatinine and estimated glomerular filtration rate) determines whether dose reduction is needed: 12.5 mg daily for moderate impairment (CrCl 30-59 mL/min) and 6.25 mg for severe impairment (CrCl 15-29 mL/min) or end-stage renal disease on dialysis. Reviewing your lab panels and learning to interpret your A1c can help you take ownership of your care between visits. Liver enzymes should be checked if symptoms of hepatic dysfunction develop, given rare post-marketing reports of hepatic failure. Home fingerstick monitoring is generally not required on alogliptin alone but is essential when it is combined with insulin or sulfonylureas like glimepiride or glipizide. Eye exams annually, urine albumin yearly, and a comprehensive foot exam at every visit remain core components of diabetes care that the medication itself cannot replace. Report severe abdominal pain radiating to the back, persistent joint pain, or new shortness of breath promptly — these can signal pancreatitis, drug-induced arthralgia, or heart failure, all of which have been observed with the DPP-4 class.

Special Populations

Dose adjustment is required in moderate to severe renal impairment, but no adjustment is needed for hepatic impairment or age alone. Older adults tolerate alogliptin well, though renal function should be checked at least annually because eGFR can decline gradually without symptoms. There are no controlled human pregnancy data; insulin remains the preferred agent during pregnancy and lactation because of its long track record and lack of placental transfer. Safety in patients under 18 has not been established. Patients with a history of pancreatitis should generally avoid DPP-4 inhibitors because of the small but real association with acute pancreatitis. Patients with prior heart failure may use alogliptin but should be monitored for fluid retention and exercise intolerance. People taking long-term warfarin, digoxin, or oral contraceptives can use alogliptin without expected interaction.

When to Contact Your Doctor

Seek immediate care for severe, persistent abdominal pain (with or without vomiting) that may radiate to the back, facial or throat swelling, blistering rash or peeling skin, or yellowing of the skin or eyes. Call the office for symptoms of heart failure (new leg swelling, weight gain of more than two to three pounds in a few days, exertional shortness of breath, orthopnea), disabling joint pain, repeated hypoglycemia when alogliptin is combined with insulin or a sulfonylurea, or any symptoms you suspect are medication-related. Do not stop the medication on your own without first checking in unless symptoms are severe, because uncontrolled hyperglycemia carries its own risks.

Patients in the Tampa Bay area also face climate-specific challenges in diabetes management. Florida heat increases the risk of dehydration and amplifies the gastrointestinal side effects of medications; learn how to navigate this in our guide on diabetes and Florida heat management and our overview of eating out with diabetes. Snowbirds with seasonal travel patterns benefit from establishing a 90-day medication supply, a portable glucose monitoring routine, and a clear plan for time-zone changes that affect dosing schedules. Pharmacy cost is another practical consideration; alogliptin is generally available as a brand-name product, while sitagliptin became generic in 2022 and may be more affordable depending on insurance coverage. Discussing total out-of-pocket cost, copay assistance programs, and 90-day fills can substantially reduce the financial barriers that lead to medication non-adherence.

If you are managing type 2 diabetes and want to review whether alogliptin or another agent best fits your overall risk profile — particularly with attention to your kidney function, cardiovascular history, weight goals, and cost considerations — contact us or schedule a visit at Zimmer Medical Group in St. Petersburg.